PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiAll Plans · Coverage · Medical Policy · Hematology, OncologyMedium impact

Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

Allogeneic hematopoietic cell transplantation may be considered medically necessary to treat chronic lymphocytic leukemia or small lymphocytic lymphoma in individuals with markers of poor-risk disease. Autologous hematopoietic cell transplantation is considered investigational to treat chronic lymphocytic leukemia or small lymphocytic lymphoma, and allogeneic transplantation is considered investigational for these conditions except as noted above. No benefits will be provided for a covered transplant procedure or a transplant evaluation unless the member receives prior authorization through Case Management from Blue Cross & Blue Shield of Mississippi.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01Billing team: Get prior authorization through Case Management from Blue Cross & Blue Shield of Mississippi before a covered transplant procedure or transplant evaluation, because no benefits will be provided without it.
02Document that allogeneic transplant (CPT 38240) for CLL or SLL is for individuals with markers of poor-risk disease, which the policy guidelines list as mutated TP53, IGHV mutation of 2% or less, del17p, del11q, or complex karyotype.
03Autologous transplant (CPT 38241) for CLL or SLL is investigational under this policy, so it should not be billed as medically necessary.
04For State and School Employee subscribers, all bone marrow and stem cell transplants must be certified as medically necessary by the Plan's Utilization Review Vendor, and no benefits will be provided for any transplant procedure unless prior approval is obtained.
05For Federal Employee Program subscribers, the Service Benefit Plan includes specific conditions in which autologous or allogeneic transplants would be considered eligible for coverage.

Codes mentioned

382043820538206382403824138242S2140S2142S2150

Original notice

Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account